Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors.

Jacqueline B Vo Cody Ramin Lene H S VeigaCarolyn BrandtRochelle E Curtis Clara Bodelon Ana Barac Véronique L Roger Heather Spencer Feigelson Diana S M BuistErin J Aiello BowlesGretchen L Gierach Amy Berrington de González

Published in: Journal of the National Cancer Institute (2024)

We found increased long-term risks of cardiomyopathy and/or HF and ischemic heart disease among breast cancer survivors treated with anthracyclines and/or trastuzumab and increased cardiomyopathy and/or HF risk among women aged younger than 65 years.

Keyphrases

cardiovascular disease
heart failure
epidermal growth factor receptor
type diabetes
metastatic breast cancer
risk assessment
metabolic syndrome
pregnant women
human health
cardiovascular risk factors
climate change